Alzheimer's Association Says Lilly's Data Showed Donanemab's Beneficial Treatment Effect Continued To Increase Relative To Placebo Over Course Of Trial; In Lilly's Study On Donanemab, 60% Participants Showed Slowing Of Decline Vs Placebo
Portfolio Pulse from Happy Mohamed
The Alzheimer's Association has reported that data from Eli Lilly's study on Donanemab showed a continued increase in beneficial treatment effect relative to placebo over the course of the trial. The study revealed that 60% of participants showed a slowing of decline compared to placebo.
July 17, 2023 | 1:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's Donanemab trial data shows positive results, with 60% of participants showing slowed decline. This could potentially boost the company's reputation and stock value.
Positive trial results are typically beneficial for pharmaceutical companies as they can lead to regulatory approval, increased sales, and a boost in stock value. Given that the trial data shows a significant slowing of decline in 60% of participants, this is likely to be viewed positively by investors and could lead to an increase in Eli Lilly's stock value in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100